Full Press Release Details
InspireMD to Announce Six-Month
Results from the MGuard Embolic Protection Stent (EPS) MASTER Trial at EuroPCR
Presence to Include Presentations/Educational
Events Featuring the MGuard
Embolic Protection Stent -
Host Conference Call on Thursday, May 23rd to Review MASTER Data -
BOSTON and TEL AVIV, Israel, MAY 16,
2013 -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection
stents, today announced a robust schedule of educational events and data presentations at EuroPCR, culminating in the first presentation
of 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial of the
Company's MGuard Embolic Protection Stent (EPS).
EuroPCR is the official annual meeting
of the European Association for Percutaneous Cardiovascular Interventions (EAPCI) and takes place in Paris, at the Palais Des Congr s,
from May 21-24, 2013.
Gregg W. Stone M.D., the MASTER study chairman
and the Director of the Cardiovascular Research and Education Center for Interventional Vascular Therapy at New York-Presbyterian
Hospital/Columbia University Medical Center, said, "In these STEMI patients, embolic protection is an unmet need that is
not addressed by current bare metal or drug eluting coronary stents. The clinical evidence supporting the benefits of using the
MGuard EPS stent in STEMI patients continues to grow. This year's EuroPCR meeting will add important new data underlining
the protective benefits of MGuard EPS six months post-procedure."
InspireMD STEMI Symposium
Thursday, May 23, 2013
12:00 CET, Room 242AB
The Embolic Protection Stent - Beyond
A More Effective Solution in STEMI Primary
The InspireMD symposium will be chaired
by Jean Fajadet, M.D., Co-Director, Interventional Cardiology Unit, Clinique Pasteur, Toulouse, France and Jose P. S. Henriques
M.D., Academic Medical Center Amsterdam, Netherlands. Additional speakers include Drs., Antonio Colombo, Ran Kornowski, Chaim Lotan
and Sigmund Silber. The highlight of the symposium will be the first presentation of 6-month results from the MASTER (MGuard
for Acute ST Elevation Reperfusion) trial of the Company's MGuard Embolic Protection Stent
A summary of additional MGuard EPS educational
events and data presentations at EuroPCR follows. All times are in Central European Time. In addition to attending these presentations,
EuroPCR participants can learn more about MGuard EPS at the InspireMD booth (#P14).
Tuesday, May 21st, 2013
12:30-14:00 Interventional strategies
for thrombus management in STEMI, Room 253
of self-expanding stents and mesh-based stents by D. Dudek
14:30-15:30 Use of adjunctive imaging
during PCI in ACS, Room 342B
14:45-14:55 OCT guided
treatment of persistent thrombus in a mesh-covered stent, by A. Thury
15:30-16:30 Primary PCI for STEMI: prevention
of thrombus embolism, Room 253
of an embolic protection stent in a STEMI case of recurrent no-reflow
16:15-16:25 Mesh-covered
stent for STEMI patient: patent side branch after stent coverage
16:45-18:15 Clot, too much clot, new
clots: primary PCI for STEMI, Room 253
17:15-17:25 Resolving
a blinded primary PCI by C. Cafri
The use of an embolic protection stent in a highly thrombotic STEMI case by B. Varshitzky
How to prevent distal embolization during PCI of diseased saphenous vein graft, Room 352A
The use of an embolic protection stent in a complex STEMI saphenous vein graft case, by I. Herz
Treating in-stent restenosis in saphenous vein graft with embolic protection stent, by I. Herz
Wednesday, May 22nd, 2013
14:10-15:40 Interactive case corner
Integrated approach with OCT,
mesh-covered stent and drug-eluting balloon for late failure of DES by M.F. Brancati
16:45-18:15 Moderated posters 3
Efficacy of an embolic protection stent as a function of symptom onset to balloon time in STEMI patients: a MASTER trial sub study
16:45-18:15 Abstract: Impact of thrombus
aspiration device on the results of primary PCI, Room 243
Efficacy of an embolic protection stent as a function of thrombus size in STEMI patients: a MASTER trial sub study by R. Costa
Thursday, May 23rd, 2013
10:45-11:45 Management of intra-coronary
thrombus during primary PCI, Room 352B
Extensive thrombotic material protrusion successfully treated with a mesh covered stent by A. Gholoobi
12:00-13:00 Corner PCI of totally occluded
saphenous vein graft, Abstract & Case Corner
12:15-12:25 STEMI due
to vein graft occlusion: new opportunities with new devices, by C. Cafri
14:10-15:40 New challenges for high-risk
primary PCI in 2013, Room 253
Case presentation: primary PCI in STEMI - What to do if standard thrombectomy and regular stent does not seem to be enough, by
14:10-15:40 Up-to-date primary PCI technique,
15:25-15:35 Novel approaches:
self-expanding, mesh covered stent, no stent, by R.J. Van Geuns
"The depth and breadth of our activities
at EuroPCR reflect InspireMD's commitment to addressing unmet needs in interventional cardiology and establishing MGuard
EPS as the industry standard for coronary stents," said Alan W. Milinazzo, President and Chief Executive Office of InspireMD.
"The MASTER trial represents a critical milestone in the evolution of the company and we are looking forward to engaging
the cardiology community in a dialogue about its implications for clinical practice at the InspireMD STEMI Symposium on May 23rd."
Conference Call and Webcast Details
InspireMD will host a conference call and
webcast to review 6-month MASTER trial data on Thursday May 23, 2013 at 8:00 ET, 14:00 CET. To access the call, participants should
dial the following numbers:
A live webcast will be available at www.inspiremd.com.
An archived webcast will be available for 30 days.
About Stenting and MGuard EPS
Standard stents were not engineered for
heart attack patients. They were designed for treating stable angina patients whose occlusion is different from that of an occlusion
in a heart attack patient.
In acute heart attack patients, the plaque
or thrombus is unstable and often breaks up as the stent is implanted causing downstream blockages (some of which can be fatal)
in a significant portion of heart attack patients.
The MGuard EPS integrates a precisely engineered
micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage from breaking
While offering superior performance relative
to standard stents in STEMI patients with regard to ST segment resolution, the MGuard EPS requires no change in current physician
practice - an important factor in promoting acceptance and general use in time-critical emergency settings.